[
  {
    "ts": null,
    "headline": "How Investors May Respond To DexCom (DXCM) Balancing Innovative Diabetes Tech Launches With Legal and Regulatory Challenges",
    "summary": "DexCom recently announced the upcoming U.S. launch of its G7 15 Day Continuous Glucose Monitoring system and received FDA clearance for its Smart Basal insulin dosing optimizer, both targeting improved accuracy and convenience for diabetes management in adults. These product advancements arrive as DexCom faces multiple class action lawsuits and regulatory scrutiny related to alleged unauthorized design changes in its G6 and G7 devices, raising questions about reliability and company...",
    "url": "https://finnhub.io/api/news?id=c8b47fed76720c0f45131f68a56eee2739bdf4ffb4dd9f7c6a7b4ef1dfc98fbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764328334,
      "headline": "How Investors May Respond To DexCom (DXCM) Balancing Innovative Diabetes Tech Launches With Legal and Regulatory Challenges",
      "id": 137628649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom recently announced the upcoming U.S. launch of its G7 15 Day Continuous Glucose Monitoring system and received FDA clearance for its Smart Basal insulin dosing optimizer, both targeting improved accuracy and convenience for diabetes management in adults. These product advancements arrive as DexCom faces multiple class action lawsuits and regulatory scrutiny related to alleged unauthorized design changes in its G6 and G7 devices, raising questions about reliability and company...",
      "url": "https://finnhub.io/api/news?id=c8b47fed76720c0f45131f68a56eee2739bdf4ffb4dd9f7c6a7b4ef1dfc98fbd"
    }
  }
]